---
title: "Definium Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285611285.md"
datetime: "2026-05-07T20:22:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285611285.md)
  - [en](https://longbridge.com/en/news/285611285.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285611285.md)
---

# Definium Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.71, missing the estimate of USD -0.4954.

EBIT: As of FY2026 Q1, the actual value is USD -61.43 M.

#### Cash, Cash Equivalents and Investments

Definium Therapeutics, Inc. reported cash, cash equivalents, and investments of $373.4 million as of March 31, 2026, a decrease from $411.6 million as of December 31, 2025.

#### Research and Development (R&D) Expenses

R&D expenses increased by $18.1 million to $41.5 million for the three months ended March 31, 2026, compared to $23.4 million for the same period in 2025. This increase was primarily driven by a $15.2 million rise in DT120 ODT program expenses, a $3.2 million increase in internal personnel costs, and a $0.3 million increase in DT402 program expenses, partially offset by a $0.6 million decrease in preclinical and other program expenses.

#### General and Administrative (G&A) Expenses

G&A expenses totaled $17.7 million for the three months ended March 31, 2026, an increase of $8.9 million from $8.8 million in the prior-year period. Key contributors to this increase included $3.9 million in stock-based compensation, $1.4 million in personnel-related expenses, $1.4 million in commercial-preparedness related expenses, $1.4 million in corporate and government affairs expenses, and $1.2 million in legal and patent expenses, partially offset by a $0.4 million reduction in other miscellaneous administrative expenses.

#### Total Operating Expenses

Total operating expenses for the three months ended March 31, 2026, were $59.22 million, up from $32.16 million for the same period in 2025.

#### Loss from Operations

The company reported a loss from operations of - $59.22 million for the three months ended March 31, 2026, compared to - $32.16 million for the three months ended March 31, 2025.

#### Other Income/(Expense)

Total other income/(expense) was - $17.88 million for the three months ended March 31, 2026, a significant change from $8.81 million in the prior-year period. This includes interest income of $3.46 million (versus $2.43 million in 2025), interest expense of - $1.25 million (versus - $0.60 million in 2025), a net foreign exchange loss of - $0.04 million (versus - $0.02 million in 2025), and a change in fair value of 2022 USD Financing Warrants of - $20.05 million (versus $7.00 million in 2025).

#### Net Loss

Definium Therapeutics, Inc. recorded a net loss of - $77.10 million for the first quarter of 2026, an increase from a net loss of - $23.35 million for the first quarter of 2025.

#### Comprehensive Loss

Comprehensive loss for the three months ended March 31, 2026, was - $77.36 million, compared to - $23.37 million for the same period in 2025.

#### Outlook / Guidance

Definium Therapeutics, Inc. anticipates three Phase 3 topline data readouts for DT120 ODT in the coming months, including Emerge (MDD) in late Q2 2026, Voyage (GAD) in early Q3 2026, and Panorama (GAD) in late Q3 2026. The company also plans to initiate the Phase 3 Haven study for DT120 ODT in PTSD in 2027. Definium Therapeutics, Inc. expects its current cash to fund operations into 2028.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis](https://longbridge.com/en/news/286901819.md)
- [Definium Therapeutics (NASDAQ:DFTX) Issues Earnings Results](https://longbridge.com/en/news/285796112.md)
- [DeFi Technologies Appoints Russell Starr as Strategic Advisor | DEFT Stock News](https://longbridge.com/en/news/286408284.md)
- [Hyperion DeFi Flags Liquidity and Earnings Volatility Risks From Rysk Vault and HYPE Options Exposure](https://longbridge.com/en/news/286663866.md)
- [THORChain Price Outlook: Panic or Opportunity After RUNE Crashes 30%?](https://longbridge.com/en/news/286643134.md)